From L-R: Johnson & Johnson CEO Joaquin Duato, Merck CEO Rob Davis and Bristol Myers Squibb CEO Chris Boerner testify in front of the Senate HELP Committee on Feb. 8, 2024 (Kevin Dietsch/Getty Images)
February 8, 2024 04:09 PM ESTUpdated 04:48 PM
Pharma

Sen­ate grills phar­ma CEOs, who emerge from hear­ing on drug prices large­ly un­scathed

Nicole DeFeudis

Editor

For about three hours on Thurs­day, sen­a­tors pressed the CEOs of Mer­ck, Bris­tol My­ers Squibb and John­son & John­son on why US drugs cost so …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times